SCHEMBL31543365

SCHEMBL31543365

CC(=O)Nc1cc2c(cn1)c(C1CC1)cn2S(=O)(=O)c1ccc(C)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TYK2 P29597 1/20 0.46
▸ PDE4A P27815 2/20 0.44
▸ PDE4B Q07343 2/20 0.44
▸ PDE4C Q08493 2/20 0.44
▸ PDE4D Q08499 2/20 0.44
▸ HTR6 P50406 3/20 0.41
▸ KDM1A O60341 1/20 0.41
▸ PIK3C3 Q8NEB9 4/20 0.40
▸ HTR1A P08908 2/20 0.40
▸ HTR1D P28221 1/20 0.40
▸ HTR1F P30939 1/20 0.40
▸ MEN1 O00255 2/20 0.40
▸ ALDH1A1 P00352 2/20 0.40
▸ LMNA P02545 2/20 0.40
▸ KMT2A Q03164 2/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ KLK7 P49862 2/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.39
▸ USP2 O75604 1/20 0.39
▸ NOD1 Q9Y239 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31543235 0.81 HTR6 (0.48) PDE4APDE4BPDE4CPDE4DHTR6
SCHEMBL31543437 0.79 HTR6 (0.43) PDE4APDE4BPDE4CPDE4DHTR6
SCHEMBL21330225 0.77 JAK1 (0.43) TYK2PDE4APDE4BPDE4CPDE4D
SCHEMBL16610233 0.75 HTR6 (0.53) HTR6HTR1AKLK7
SCHEMBL16610232 0.72 SCN9A (0.44) HTR6
SCHEMBL18080762 0.71 HTR6 (0.49) HTR6HTR1AKLK7
SCHEMBL30974647 0.71 HTR6 (0.54) HTR6KLK7
SCHEMBL24377801 0.69 TYK2 (0.53) TYK2PIK3C3HTR1AHTR1DHTR1F
SCHEMBL24377848 0.69 TYK2 (0.53) TYK2PIK3C3HTR1AHTR1DHTR1F
SCHEMBL30632840 0.69 TYK2 (0.47) TYK2PIK3C3HTR1AHTR1DHTR1F

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250304577-A1 TYK2 INHIBITORS BIOGEN MA INC. 2025-10-02 — — US disclosed
CN-119654322-A TYK2 inhibitors 渤健马萨诸塞州股份有限公司 2025-03-18 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250304577-A1 TYK2 INHIBITORS TYK2, JAK2, JAK1 TYK2 1/4885PDE4A 3830/4885PDE4B 3407/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback